The Public Summary Document for Lilly's biologic for chronic migraine EMGALITY (galcanezumab) shows the company facing what could still be a challenging path to reimbursement. …
Migraine biologics might still face a challenging path to the PBS
March 22, 2021 Latest NewsBioPharma
Latest Video
New Stories
-
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 - -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 13 November
November 13, 2026 - - Podcast -
A year on, Sanofi now asks staff to explain how they used AI
November 13, 2026 - - Latest News -
There is no need for AI to automate the care out of healthcare, Cohn warns
November 13, 2026 - -
Cochlear's global government affairs chief is putting AI to work
November 13, 2026 - - Latest News